Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 1.1% year-over-year to $3.0 billion in Q1 2026; TTM through Mar 2026 was $3.0 billion, a 1.1% increase from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 6.55% from the prior year.
• Accumulated Expenses was little changed at $3.0 billion in Q1 2026 per VRTX's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.6 billion in Q3 2025 and bottomed at $1.7 billion in Q1 2022.
• The 5-year median for Accumulated Expenses is $2.8 billion (2024), against an average of $2.7 billion.
• Across the five-year window, Accumulated Expenses surged 42.96% in 2022 and gained 1.1% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $2.1 billion in 2022, then advanced by 24.86% to $2.7 billion in 2023, then grew by 5.02% to $2.8 billion in 2024, then advanced by 6.55% to $3.0 billion in 2025, then rose by 0.44% to $3.0 billion in 2026.
• Per Business Quant, the three latest VRTX Accumulated Expenses figures stand at $3.0 billion (Q1 2026), $3.0 billion (Q4 2025), and $3.6 billion (Q3 2025).